Drug Profile
SQ 885
Latest Information Update: 29 Mar 2008
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class
- Mechanism of Action Angiogenesis inhibitors; Integrin alphaVbeta3 antagonists; Integrin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Eye disorders; Inflammation; Solid tumours
Most Recent Events
- 24 Aug 1999 New profile
- 24 Aug 1999 Preclinical development for Eye disorders in USA (Unknown route)
- 24 Aug 1999 Preclinical development for Inflammation in USA (Unknown route)